Checkpoint inhibitor

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma

Retrieved on: 
Thursday, August 13, 2020
Medicine, Clinical medicine, RTT, Cancer, Melanoma, Checkpoint inhibitor, Health, Bristol-Myers Squibb, Cancer immunotherapy, Ipilimumab

Dr Victoria Gordon, Managing Director and CEO of QBiotics, said, "We are delighted to announce this collaboration with MSD.

Key Points: 
  • Dr Victoria Gordon, Managing Director and CEO of QBiotics, said, "We are delighted to announce this collaboration with MSD.
  • Patients with unresectable melanoma who have received prior checkpoint inhibitors currently have limited effective treatment options.
  • Secondary measures include assessing tumour responses in both injected tumours and uninjected tumours, as well as clinical efficacy parameters.
  • Patients with unresectable melanoma and who have had exposure to immune checkpoint inhibitors are eligible for the study.

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma

Retrieved on: 
Thursday, August 13, 2020
Medicine, Clinical medicine, RTT, Cancer, Melanoma, Checkpoint inhibitor, Health, Bristol-Myers Squibb, Cancer immunotherapy, Ipilimumab

Dr Victoria Gordon, Managing Director and CEO of QBiotics, said, "We are delighted to announce this collaboration with MSD.

Key Points: 
  • Dr Victoria Gordon, Managing Director and CEO of QBiotics, said, "We are delighted to announce this collaboration with MSD.
  • Patients with unresectable melanoma who have received prior checkpoint inhibitors currently have limited effective treatment options.
  • Secondary measures include assessing tumour responses in both injected tumours and uninjected tumours, as well as clinical efficacy parameters.
  • Patients with unresectable melanoma and who have had exposure to immune checkpoint inhibitors are eligible for the study.

Oncocyte to Hold KOL Webinar Highlighting Clinical Data on Its DetermaIO™ Test for Immunotherapy Response Prediction

Retrieved on: 
Tuesday, August 11, 2020
Cancer immunotherapy, Clinical medicine, Medicine, Cancer, Triple-negative breast cancer, Immunotherapy, Non-small-cell lung carcinoma, Checkpoint inhibitor, AXL receptor tyrosine kinase

The webinar will be held on Wednesday, August 19th at 11:30 a.m. PDT and is open to both clinicians and investors.

Key Points: 
  • The webinar will be held on Wednesday, August 19th at 11:30 a.m. PDT and is open to both clinicians and investors.
  • DetermaIO is currently available to pharmaceutical companies for use in research and clinical trials only.
  • The webinar will review clinical studies that assessed the association of tumor classification using DetermaIO with response to checkpoint inhibitor therapy in NSCLC and Triple Negative Breast Cancer (TNBC).
  • Oncocyte is also developing DetermaIO, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology

Retrieved on: 
Tuesday, August 4, 2020
Clusters of differentiation, Immune system, Clinical medicine, Medicine, Immunology, Cancer immunotherapy, PD-L1, Checkpoint inhibitor, Immune checkpoint, Tumor microenvironment, PTPN11, L1

Additionally, SHP2 interaction with PD-L1 (an immune checkpoint molecule) results in the inhibition of T cell activity in the tumor microenvironment.

Key Points: 
  • Additionally, SHP2 interaction with PD-L1 (an immune checkpoint molecule) results in the inhibition of T cell activity in the tumor microenvironment.
  • The possibility of SHP2 inhibition to enhance T-cell immunity is of enormous potential relative to the success of PD-L1 checkpoint inhibitors in oncology.
  • As a result, SHP2 multi-functions in tumor progression, cancer cell growth and suppression of anti-tumor immunity, further demonstrating development of SHP2 inhibitors for unmet clinical need.
  • HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in international markets.

Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers

Retrieved on: 
Wednesday, July 22, 2020
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, RTT, Clinical medicine, Medicine, Papillomavirus, Cancer immunotherapy, Human papillomavirus infection, Checkpoint inhibitor, Cancer, HPV-positive oropharyngeal cancer

This analysis confirms that TG4001 can be safely combined with an immune checkpoint inhibitor and shows clinical activity of this combination regimen.

Key Points: 
  • This analysis confirms that TG4001 can be safely combined with an immune checkpoint inhibitor and shows clinical activity of this combination regimen.
  • Clinical activity was observed in the overall study population (34 evaluable patients with oropharyngeal, anal, cervical, or other HPV16-positive cancers).
  • In addition, Transgene has identified a selection criterion corresponding to patients showing particularly promising clinical activity in this trial.
  • The Company intends to continue the clinical development of TG4001 in a larger, controlled confirmatory study.

TRACON Pharmaceuticals Announces Filing of Protocol for ENVASARC Pivotal Trial with the FDA

Retrieved on: 
Thursday, July 16, 2020
Neoplasms, Cancer, Clinical medicine, Checkpoint inhibitor, Sarcoma, Undifferentiated pleomorphic sarcoma, Histiocytoma, Soft-tissue sarcoma, Fibrosarcoma

TRACON previously reported results of a May 8 teleconference with the FDA whereby the agency agreed with TRACONs proposals regarding key elements of the pivotal ENVASARC trial for envafolimab in the soft tissue sarcoma subtypes of undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS).

Key Points: 
  • TRACON previously reported results of a May 8 teleconference with the FDA whereby the agency agreed with TRACONs proposals regarding key elements of the pivotal ENVASARC trial for envafolimab in the soft tissue sarcoma subtypes of undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS).
  • TRACON expects to initiate enrollment in the ENVASARC trial at 25 sites in the U.S. in the second half of 2020.
  • Key elements for the ENVASARC pivotal trial include:
    Eligible patients will have received one or two prior cancer therapies, but no prior immune checkpoint inhibitor therapy.
  • TRACON undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Biodesix Pipeline Test Identifies Patients Who Are Likely to Respond to Immune Checkpoint Inhibitors

Retrieved on: 
Thursday, July 16, 2020
Oncology, Health, Clinical trials, Research, Science, Biotechnology, Clinical medicine, Medicine, Drugs, Cancer treatments, Monoclonal antibodies, Breakthrough therapy, Bristol-Myers Squibb, Non-small-cell lung carcinoma, Nivolumab, Lung cancer, Checkpoint inhibitor, Treatment of lung cancer

The 289 enrolled patients were stratified into three groups after receiving second-line treatment: good (sensitive), intermediate and poor (resistant).

Key Points: 
  • The 289 enrolled patients were stratified into three groups after receiving second-line treatment: good (sensitive), intermediate and poor (resistant).
  • Pooled analysis demonstrated significantly better overall survival rates for "sensitive" relative to "resistant" patients treated with nivolumab.
  • The study demonstrated that this serum-derived proteomic signature successfully stratified outcomes in groups of advanced NSCLC patients treated with second line PD-1 checkpoint inhibitors.
  • Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung.

New Drug Developments and Combinations Aiding Badly Neglected Triple-Negative Breast Cancer Patients

Retrieved on: 
Wednesday, July 15, 2020
Medicine, Clinical medicine, Cancer treatments, Immune system, Breast cancer, Triple-negative breast cancer, PD-L1, Atezolizumab, Checkpoint inhibitor, Programmed cell death protein 1, Breakthrough therapy, Pelareorep

Dr. George added: "Checkpoint inhibitors targeting interactions between PD-L1 and PD-1, while commercially successful, are ineffective in up to 80% of TNBC patients.

Key Points: 
  • Dr. George added: "Checkpoint inhibitors targeting interactions between PD-L1 and PD-1, while commercially successful, are ineffective in up to 80% of TNBC patients.
  • Clinical data show that systemic pelareorep administration can upregulate PD-L1 expression in tumors across multiple breast cancer subtypes, highlighting its potential to substantially increase the percentage of patients who respond to checkpoint inhibitor therapy.
  • Last year, Tecentriq made history as the first immune-oncology agent to win an FDA approval in triple-negative breast cancer (TNBC).
  • The drug was approved to treat patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies.

New Drug Developments and Combinations Aiding Badly Neglected Triple-Negative Breast Cancer Patients

Retrieved on: 
Wednesday, July 15, 2020
Medicine, Clinical medicine, Cancer treatments, Immune system, Breast cancer, Triple-negative breast cancer, PD-L1, Atezolizumab, Checkpoint inhibitor, Programmed cell death protein 1, Breakthrough therapy, Pelareorep

Dr. George added: "Checkpoint inhibitors targeting interactions between PD-L1 and PD-1, while commercially successful, are ineffective in up to 80% of TNBC patients.

Key Points: 
  • Dr. George added: "Checkpoint inhibitors targeting interactions between PD-L1 and PD-1, while commercially successful, are ineffective in up to 80% of TNBC patients.
  • Clinical data show that systemic pelareorep administration can upregulate PD-L1 expression in tumors across multiple breast cancer subtypes, highlighting its potential to substantially increase the percentage of patients who respond to checkpoint inhibitor therapy.
  • Last year, Tecentriq made history as the first immune-oncology agent to win an FDA approval in triple-negative breast cancer (TNBC).
  • The drug was approved to treat patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies.

Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

Retrieved on: 
Thursday, July 9, 2020
Medicine, Clinical medicine, Cancer, Checkpoint inhibitor, Immune system, Monoclonal antibodies, Tyrosine kinase inhibitors

The initiation of this Phase 1/2 clinical trial is a key advancement in our NT219 development program, said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Kitov.

Key Points: 
  • The initiation of this Phase 1/2 clinical trial is a key advancement in our NT219 development program, said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Kitov.
  • I look forward to dosing of the first patients in this trial shortly.
  • The primary objectives of the open-label Phase 1/2 trial are to evaluate safety, assess pharmacokinetics, identify the recommended dose to be studied in the Phase 2 portion, and establish preliminary efficacy of NT219.
  • Kitov plans to advance CM-24 as a combination therapy with anti-PD1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer NSCLC and pancreatic cancer.